Depression and Anxiety in Rheumatoid Arthritis

University of Pavia200 enrolled

Overview

The primary endpoint of this study is to evaluate the prevalence of anxiety and depressive disorders, and their relationship with disease activity, in patients with rheumatoid arthritis treated with biological drugs

The prevalence of anxiety and depressive disorders will be assesed with the HADS questionnaire at the time of the visit

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Rheumatoid Arthritis Depression Anxiety

Interventions

Hospital Anxiety and Depression Scale (HADS) questionnaireOTHER

Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \>18 years * diagnosis of rheumatoid arthritis according to 2010 Classification American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Criteria * being able to compile questionnaire * current treatment with biological disease-modifying antirheumatic drug Exclusion Criteria: * Current treatment for anxiety or depressive disorder

Locations (1)

IRCCS policlinico San Matteo - Reparto di Reumatologia

Pavia, PV, Italy

Outcomes

Primary Outcomes

Hospital Anxiety and Depression Scale (HADS)

Hospital Anxiety and Depression Scale (HADS) questionnaire. The HADS is a fourteen item scale. Seven of the items relate to anxiety and seven relate to depression. The anxiety and depression subscales each range from 0 to 21, with higher scores indicating higher anxiety/depression complains. Patients were defined as having anxiety or depression or both if the score was 8 or more in the corresponding subscale.

Time frame: 1 day of enrollement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.